Tofacitinib Impurity 6
|
|
Tofacitinib Impurity 6 속성
- 녹는점
- >80°C (dec.)
- 끓는 점
- 583.2±50.0 °C(Predicted)
- 밀도
- 1.239±0.06 g/cm3(Predicted)
- 저장 조건
- -20°C Freezer
- 용해도
- DMSO(약간 용해됨), 메탄올(약간 용해됨)
- 산도 계수 (pKa)
- 6.04±0.60(Predicted)
- 물리적 상태
- 고체
- 물리적 상태
- 단단한 모양
- 색상
- 연한 노란색에서 노란색까지
안전
Tofacitinib Impurity 6 C화학적 특성, 용도, 생산
용도
5,6-Dihydro CP-690550 is an impurity of CP-690550 (C781350), a pyrrolo[2,3-d]pyrimidine derivative, as Janus kinase inhibitor for treatment of rheumatoid arthritis.Tofacitinib Impurity 6 준비 용품 및 원자재
원자재
준비 용품
Tofacitinib Impurity 6 공급 업체
글로벌( 57)공급 업체
공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
---|---|---|---|---|---|
Standardpharm Co. Ltd. | 86-714-3992388 |
overseasales1@yongstandards.com | United States | 14336 | 58 |
career henan chemical co | +86-0371-86658258 +8613203830695 |
factory@coreychem.com | China | 29826 | 58 |
ANHUI WITOP BIOTECH CO., LTD | +8615255079626 |
eric@witopchemical.com | China | 23556 | 58 |
China National Standard Pharmaceutical Corporation Limited | +8615391658522 |
overseasales@yongstandards.com | China | 11927 | 58 |
ShenZhen H&D Pharmaceutical Technology Co., LTD | +86-0755-22677845 +86-13627253706 |
sale@hdimpurity.com | China | 3154 | 58 |
Suzhou ARTK Medchem Co., Ltd. | +8618168183658 |
sales1@artkmedchem.com | China | 39009 | 58 |
Shanghai Payne Pharmaceutical Technology Co.Ltd | 021-58123769 18678586262 |
info@paynepharm.com | China | 1354 | 58 |
Nanjing wangzhixing Pharmaceutical Technology Co., Ltd | 15850510341 |
shiqingran@wzxchem.com | China | 3636 | 58 |
Hubei Ruinuo Pharmaceutical Technology Co., Ltd | 13165688766 |
3008058303@qq.com | China | 5000 | 58 |
S.Z. PhyStandard Bio-Tech. Co., Ltd. | 0755-4000505016 13380397412 |
3001272453@qq.com | China | 4963 | 50 |
Tofacitinib Impurity 6 관련 검색:
Tofacitinib related coMpound 2
3-((3S,4S)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile
3-((3R,4R)-3-((2-chloro-7H-pyrrolo[2,3-d]pyriMidin-4-yl)(Methyl)aMino)-4-Methylpiperidin-1-yl)-3-oxopropanenitrile
Tofacitinib Impurity 2
Tofacitinib Impurity 3
3-Amino-4-methylpyridine
N-((3S,4S)-1-benzyl-4-Methylpiperidin-3-yl)-N-Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-aMine
Methyl (1-benzyl-4-Methylpiperidin-3-yl)carbaMate
13-Deoxyepirubicin
3-((3R,4S)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanenitrile
N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine
3-METHOXYCARBONYLAMINO-4-METHYLPYRIDINE
1-[2-(2-methoxyphenoxy)ethylamino]-3-(9-methylcarbazol-4-yl)oxypropan-2-ol:hydrochloride
7H-Pyrrolo[2,3-d]pyriMidin-4-aMine, N-Methyl-N-[(3R,4R)-4-Methyl-1-(phenylMethyl)-3-piperidinyl]-7-[(4-Met hylphenyl)sulfonyl]-
Methyl (4-Methylpiperidin-3-yl)carbaMate
3-((3S,4R)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanenitrile
4-CHLORO-7-TOSYL-7H-PYRROLO[2,3-D]PYRIMIDINE
3-PiperidinaMine, 1-acetyl-N,4-diMethyl-N-1H-pyrrolo[2,3-d]pyriMidin-4-yl-, (3R,4R)- (9CI)